BridgeBio Pharma rises on market strength and technical indicator
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 15 2024
0mins
Should l Buy BBIO?
Source: NASDAQ.COM
BridgeBio Pharma Inc. saw a price increase of 5.03% as it crossed above its 5-day SMA, reflecting positive momentum in the stock.
This movement is attributed to broad market strength, with the Nasdaq-100 up 0.90% and the S&P 500 up 0.58%, indicating a favorable environment for stocks in the biotech sector. The overall market conditions have contributed to investor confidence, enhancing the stock's performance.
As the company continues to navigate the competitive landscape of biotechnology, this upward movement may attract further interest from investors looking for growth opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BBIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BBIO
Wall Street analysts forecast BBIO stock price to rise
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 70.720
Low
85.00
Averages
98.50
High
157.00
Current: 70.720
Low
85.00
Averages
98.50
High
157.00
About BBIO
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Worst Performing Large-Cap Stocks Last Week
- GPC Earnings Miss: Genuine Parts Company (NYSE:GPC) saw a 19.51% drop this week after reporting disappointing fourth-quarter results and issuing FY26 EPS guidance below estimates, prompting multiple analysts to lower their price targets, indicating market concerns over its future profitability.
- FLUT Earnings Awaited: Flutter Entertainment plc (NYSE:FLUT) decreased by 11.86% this week as the company announced it will release its fourth quarter and full year 2025 financial results after market close on February 26, leading investors to adopt a cautious stance ahead of the earnings report, which may impact stock performance.
- OKTA Price Target Cuts: Okta, Inc. (NASDAQ:OKTA) fell 12.86% this week after several firms lowered their price targets, reflecting diminished market confidence in its growth potential and possibly prompting investors to reassess its investment value.
- TEAM Executive Change: Atlassian Corporation (NASDAQ:TEAM) decreased by 5.33% this week following the announcement of James Chuong as the new Chief Financial Officer effective March 30, 2026; while executive changes may bring new strategic directions, they failed to boost the stock price in the short term.
See More
Cormorant Increases MoonLake Stake Above 6%
- Stake Increase: Cormorant Asset Management disclosed on Tuesday that it has increased its stake in MoonLake Immunotherapeutics to 4.36 million shares, representing a 6.1% ownership, up from about 2 million shares in October 2025, indicating strong confidence in the company's future and potential stock price impact.
- Significant Stock Surge: Following the news of Cormorant's increased stake, MoonLake's shares jumped 11% on Tuesday, marking the largest rally in over a month, reflecting heightened market interest in a possible takeover and potentially attracting more investors.
- Market Sentiment Shift: Retail sentiment for MLTX on Stocktwits flipped from 'extremely bearish' to 'extremely bullish' with a 900% surge in message volume over 24 hours, indicating strong investor expectations for the company's future, which could further drive stock price increases.
- FDA Fast Track Progress: MoonLake's Sonelokimab received FDA Fast Track designation, with plans to pursue a biologics license application in the second half of 2026, highlighting the company's potential in the treatment space and likely drawing increased institutional investor interest in its long-term growth prospects.
See More
BridgeBio Pharma Approves Employee Equity Grants
- Equity Grant Program: On February 12, 2026, BridgeBio Pharma approved equity grants totaling 76,701 restricted stock units to 34 new employees, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in genetic drug development.
- Vesting Schedule: One-fourth of the restricted stock units will vest on February 16, 2027, with the remaining shares vesting quarterly, ensuring employees remain with the company to receive their incentives, which boosts employee loyalty and motivation.
- Compliance and Plan Background: The equity grants comply with Nasdaq Listing Rule 5635(c)(4) and are granted under an incentive plan adopted in November 2019, demonstrating the company's strategic planning and compliance in talent acquisition.
- Company Mission and Vision: BridgeBio focuses on developing transformative medicines for genetic conditions, aiming to bridge the gap between advancements in genetic science and patient needs, utilizing a decentralized operational model to enhance R&D efficiency and market responsiveness.
See More
BridgeBio to Release Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: BridgeBio Pharma will announce its fourth quarter and full year 2025 financial results after market close on February 24, 2026, highlighting the company's latest advancements and financial status in the genetic treatment sector.
- Conference Call Details: The company will host a conference call at 4:30 PM ET on the same day to discuss the financial results and program updates, aiming to bolster investor confidence in the company's future growth.
- Webcast Access: Investors can access the live webcast of the earnings release through the 'Events & Presentations' page on BridgeBio's website, ensuring transparency and fostering interaction with stakeholders.
- Company Mission and Model: BridgeBio focuses on developing transformative medicines for genetic conditions, utilizing a decentralized hub-and-spoke model to enhance the speed and precision of drug development, addressing the needs of small patient populations.
See More
BridgeBio Pharma Stock Soars on Positive Clinical Trial Results
- Clinical Trial Results: BridgeBio Pharma's PROPEL 3 Phase 3 trial for oral infigratinib in children demonstrated a significant annualized height velocity increase, with an LS mean treatment difference of +1.74 cm/year compared to placebo, highlighting the drug's potential in treating achondroplasia.
- Statistical Significance: In a pre-specified exploratory analysis of children under 8, infigratinib showed statistical significance against placebo with an LS mean decrease of -0.05, marking a significant breakthrough in randomized trials for achondroplasia treatment.
- Regulatory Plans: BridgeBio intends to meet with regulatory authorities in the second half of 2026 to discuss plans for submitting a New Drug Application (NDA) and Marketing Authorization Application (MAA) for infigratinib, reflecting the company's confidence in future market opportunities.
- Competitive Landscape: While BioMarin's Voxzogo is the first FDA-approved drug for achondroplasia, the positive results from BridgeBio's infigratinib clinical trials may shift the competitive dynamics and enhance the company's position in the rare disease market.
See More
BRIDGEBIO STOCK RISES 10.44% FOLLOWING FAVORABLE LATE-STAGE TRIAL OUTCOMES FOR ORAL GENETIC DISORDER TREATMENT
Positive Trial Results: BridgeBio's drug for treating an oral genetic disorder has shown a 10.44% improvement in late-stage trial results.
Impact on Patients: The positive outcomes from the trial suggest potential benefits for patients suffering from this specific genetic condition.
See More
Worst Performing Large-Cap Stocks Last Week
- GPC Earnings Miss: Genuine Parts Company (NYSE:GPC) saw a 19.51% drop this week after reporting disappointing fourth-quarter results and issuing FY26 EPS guidance below estimates, prompting multiple analysts to lower their price targets, indicating market concerns over its future profitability.
- FLUT Earnings Awaited: Flutter Entertainment plc (NYSE:FLUT) decreased by 11.86% this week as the company announced it will release its fourth quarter and full year 2025 financial results after market close on February 26, leading investors to adopt a cautious stance ahead of the earnings report, which may impact stock performance.
- OKTA Price Target Cuts: Okta, Inc. (NASDAQ:OKTA) fell 12.86% this week after several firms lowered their price targets, reflecting diminished market confidence in its growth potential and possibly prompting investors to reassess its investment value.
- TEAM Executive Change: Atlassian Corporation (NASDAQ:TEAM) decreased by 5.33% this week following the announcement of James Chuong as the new Chief Financial Officer effective March 30, 2026; while executive changes may bring new strategic directions, they failed to boost the stock price in the short term.
See More
Cormorant Increases MoonLake Stake Above 6%
- Stake Increase: Cormorant Asset Management disclosed on Tuesday that it has increased its stake in MoonLake Immunotherapeutics to 4.36 million shares, representing a 6.1% ownership, up from about 2 million shares in October 2025, indicating strong confidence in the company's future and potential stock price impact.
- Significant Stock Surge: Following the news of Cormorant's increased stake, MoonLake's shares jumped 11% on Tuesday, marking the largest rally in over a month, reflecting heightened market interest in a possible takeover and potentially attracting more investors.
- Market Sentiment Shift: Retail sentiment for MLTX on Stocktwits flipped from 'extremely bearish' to 'extremely bullish' with a 900% surge in message volume over 24 hours, indicating strong investor expectations for the company's future, which could further drive stock price increases.
- FDA Fast Track Progress: MoonLake's Sonelokimab received FDA Fast Track designation, with plans to pursue a biologics license application in the second half of 2026, highlighting the company's potential in the treatment space and likely drawing increased institutional investor interest in its long-term growth prospects.
See More
BridgeBio Pharma Approves Employee Equity Grants
- Equity Grant Program: On February 12, 2026, BridgeBio Pharma approved equity grants totaling 76,701 restricted stock units to 34 new employees, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in genetic drug development.
- Vesting Schedule: One-fourth of the restricted stock units will vest on February 16, 2027, with the remaining shares vesting quarterly, ensuring employees remain with the company to receive their incentives, which boosts employee loyalty and motivation.
- Compliance and Plan Background: The equity grants comply with Nasdaq Listing Rule 5635(c)(4) and are granted under an incentive plan adopted in November 2019, demonstrating the company's strategic planning and compliance in talent acquisition.
- Company Mission and Vision: BridgeBio focuses on developing transformative medicines for genetic conditions, aiming to bridge the gap between advancements in genetic science and patient needs, utilizing a decentralized operational model to enhance R&D efficiency and market responsiveness.
See More
BridgeBio to Release Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: BridgeBio Pharma will announce its fourth quarter and full year 2025 financial results after market close on February 24, 2026, highlighting the company's latest advancements and financial status in the genetic treatment sector.
- Conference Call Details: The company will host a conference call at 4:30 PM ET on the same day to discuss the financial results and program updates, aiming to bolster investor confidence in the company's future growth.
- Webcast Access: Investors can access the live webcast of the earnings release through the 'Events & Presentations' page on BridgeBio's website, ensuring transparency and fostering interaction with stakeholders.
- Company Mission and Model: BridgeBio focuses on developing transformative medicines for genetic conditions, utilizing a decentralized hub-and-spoke model to enhance the speed and precision of drug development, addressing the needs of small patient populations.
See More
BridgeBio Pharma Stock Soars on Positive Clinical Trial Results
- Clinical Trial Results: BridgeBio Pharma's PROPEL 3 Phase 3 trial for oral infigratinib in children demonstrated a significant annualized height velocity increase, with an LS mean treatment difference of +1.74 cm/year compared to placebo, highlighting the drug's potential in treating achondroplasia.
- Statistical Significance: In a pre-specified exploratory analysis of children under 8, infigratinib showed statistical significance against placebo with an LS mean decrease of -0.05, marking a significant breakthrough in randomized trials for achondroplasia treatment.
- Regulatory Plans: BridgeBio intends to meet with regulatory authorities in the second half of 2026 to discuss plans for submitting a New Drug Application (NDA) and Marketing Authorization Application (MAA) for infigratinib, reflecting the company's confidence in future market opportunities.
- Competitive Landscape: While BioMarin's Voxzogo is the first FDA-approved drug for achondroplasia, the positive results from BridgeBio's infigratinib clinical trials may shift the competitive dynamics and enhance the company's position in the rare disease market.
See More
BRIDGEBIO STOCK RISES 10.44% FOLLOWING FAVORABLE LATE-STAGE TRIAL OUTCOMES FOR ORAL GENETIC DISORDER TREATMENT
Positive Trial Results: BridgeBio's drug for treating an oral genetic disorder has shown a 10.44% improvement in late-stage trial results.
Impact on Patients: The positive outcomes from the trial suggest potential benefits for patients suffering from this specific genetic condition.
See More
